Literature DB >> 25132785

Selection of treatment modalities for Budd-Chiari Syndrome in China: a preliminary survey of published literature.

Xing-Shun Qi1, Wei-Rong Ren1, Dai-Ming Fan1, Guo-Hong Han1.   

Abstract

AIM: To evaluate the frequency of use of various treatment modalities for Budd-Chiari syndrome (BCS) in China by conducting a preliminary survey of relevant literature.
METHODS: All papers regarding the treatment of BCS in Chinese patients were identified by searching PubMed, Chinese Scientific and Technological Journal, and China National Knowledge Infrastructure databases. Data regarding the number of BCS patients treated with different treatment modalities over time were collected. The proportions of BCS patients undergoing various treatment modalities were calculated.
RESULTS: Overall, 300 of 3005 papers initially retrieved were included. These papers included 23352 BCS patients treated with different treatment modalities. The treatment modalities include surgery (n = 8625), interventional treatment (n = 13940), surgery combined with interventional treatment (n = 363), medical therapy (n = 277), other treatments (n = 91), and no treatment (n = 56). After 2005, the number of BCS patients treated with surgery was drastically decreased, but the number of BCS patients who underwent interventional treatment was almost maintained. Shunt surgery was the most common type of surgery (n = 3610). Liver transplantation was rarely employed (n = 2). Balloon angioplasty with or without stenting was the most common type of interventional treatment (n = 13747). Transjugular intrahepatic portosystemic shunt was rarely employed (n = 81).
CONCLUSION: Selection of treatment modalities for BCS might be different between China and Western countries. Further work should be necessary to establish a unanimous therapeutic strategy for BCS in China.

Entities:  

Keywords:  Budd-Chiari syndrome; Percutaneous recanalization; Surgery; Transjugular intrahepatic portosystemic shunt; Treatment

Mesh:

Year:  2014        PMID: 25132785      PMCID: PMC4130876          DOI: 10.3748/wjg.v20.i30.10628

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  Budd-Chiari syndrome: a review by an expert panel.

Authors:  Harry L A Janssen; Juan-Carlos Garcia-Pagan; Elwyn Elias; Gilles Mentha; Antoine Hadengue; Dominique-Charles Valla
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

Review 2.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

3.  Surgical treatment of 1360 cases of Budd-Chiari syndrome: 20-year experience.

Authors:  Pei-Qin Xu; Xiu-Xian Ma; Xue-Xiang Ye; Liu-Shun Feng; Xiao-Wei Dang; Yong-Fu Zhao; Shui-Jun Zhang; Long-Shuan Zhao; Zhe Tang; Xiu-Bo Lu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2004-08

4.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

5.  Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome.

Authors:  Aurélie Plessier; Annie Sibert; Yann Consigny; Antoine Hakime; Magaly Zappa; Marie-Hélène Denninger; Bertrand Condat; Olivier Farges; Carine Chagneau; Victor de Ledinghen; Claire Francoz; Alain Sauvanet; Valérie Vilgrain; Jacques Belghiti; François Durand; Dominique Valla
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

6.  Evolution of management for Budd-Chiari syndrome: a team's view from 2564 patients.

Authors:  Zhong Gao Wang; Feng Ji Zhang; Meng Qing Yi; Li Xiao Qiang
Journal:  ANZ J Surg       Date:  2005 Jan-Feb       Impact factor: 1.872

7.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

8.  Modified transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome.

Authors:  X Wu; W Ding; J Cao; J Han; J Li
Journal:  Int J Clin Pract       Date:  2008-04-23       Impact factor: 2.503

9.  Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome.

Authors:  Chun-Qing Zhang; Li-Na Fu; Lin Xu; Guo-Quan Zhang; Tao Jia; Ji-Yong Liu; Cheng-Yong Qin; Ju-Ren Zhu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 10.  Primary Budd-Chiari syndrome.

Authors:  Dominique-Charles Valla
Journal:  J Hepatol       Date:  2008-10-26       Impact factor: 25.083

View more
  8 in total

1.  Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.

Authors:  Zhong-Ke Chen; Jing Fan; Chi Cao; Yu Li
Journal:  Radiol Med       Date:  2018-05-31       Impact factor: 3.469

Review 2.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

3.  Evaluation of dangerous collateral vessels and thrombus in Budd-Chiari syndrome patients with inferior vena cava obstruction.

Authors:  Dehan Liu; Qianqian Ren; Tianhe Ye; Chuansheng Zheng; Yangbo Su; Xiangwen Xia
Journal:  Abdom Radiol (NY)       Date:  2021-12-09

4.  Budd-Chiari syndrome in China: A 30-year retrospective study on survival from a single center.

Authors:  Wei Zhang; Qiao-Zheng Wang; Xiao-Wei Chen; Hong-Shan Zhong; Xi-Tong Zhang; Xu-Dong Chen; Ke Xu
Journal:  World J Gastroenterol       Date:  2018-03-14       Impact factor: 5.742

5.  Timing of Transjugular Intrahepatic Portosystemic Stent-shunt in Budd-Chiari Syndrome: A UK Hepatologist's Perspective.

Authors:  Faisal Khan; Homoyon Mehrzad; Dhiraj Tripathi
Journal:  J Transl Int Med       Date:  2018-10-09

6.  Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model.

Authors:  De-Lei Cheng; Nan Zhu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Ya Liu; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

7.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

8.  Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China.

Authors:  Peijin Zhang; Yanyan Zhang; Jing Zhang; Hui Wang; He Ma; Wei Wang; Xiuyin Gao; Hao Xu; Zhaojun Lu
Journal:  Gastroenterol Res Pract       Date:  2015-10-18       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.